ArticleBMC cancer2021
The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Claudin 18 is not a biomarker for breast mucinous tumor.Journal of the Chinese Medical Association : JCMA · 2026Article
- A Case Requiring Differential Diagnosis of Synovitis, Acne, Pustulosis, Hyperostosis, Osteomyelitis Syndrome in the Evaluation of Bone Lesions in Early Breast Cancer.Surgical case reports · 2026Article
- Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology.Discover oncology · 2025Article
- Clinicopathological features and prognosis of mucinous breast carcinoma with a micropapillary structure.Thoracic cancer · 2024Article
- Article
- Axillary lymph node metastasis in pure mucinous carcinoma of breast: clinicopathologic and ultrasonographic features.BMC medical imaging · 2024Article
- Response of mucinous breast carcinoma to neoadjuvant chemotherapy.Turkish journal of medical sciences · 2024Article
- Clinical implications of forkhead box M1, cyclooxygenase-2World journal of clinical cases · 2023Article
- Breast-conserving surgery is an appropriate procedure for centrally located breast cancer: a population-based retrospective cohort study.BMC surgery · 2023Article
- Clinical Features and Prognoses of Patients With Breast Cancer Who Underwent Surgery.JAMA network open · 2023Article
- On Ultrasonographic Features of Mucinous Carcinoma with Micropapillary Pattern.Breast cancer (Dove Medical Press) · 2023Article
- A novel nomogram and risk classification system for predicting lymph node metastasis of breast mucinous carcinoma: A SEER-based study.Cancer medicine · 2022Article
- Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes.European journal of breast health · 2022Article
- Development and validation of prognostic nomograms in patients with gallbladder mucinous adenocarcinoma: A population-based study.Frontiers in oncology · 2022Article
- Construction and Validation of New Nomograms to Predict Risk and Prognostic Factors of Breast Cancer Bone Metastasis in Asian Females: A Population-Based Retrospective Study.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present, the characteristics of mucinous breast carcinoma (MBC) and the factors affecting its prognosis are controversial. We compared the clinical features of MBC with those of infiltrating ductal carcinoma (IDC) and summarized the relevant prognostic factors.
methodsThe Surveillance, Epidemiology, and End Results (SEER) database includes information on 10,593 patients diagnosed with MBC between 2004 and 2016. Chi-square tests and analyses were used to analyze differences in variables between the MBC and IDC groups. Univariate and multivariate Cox proportional hazards models were used to assess the relative impacts of risk factors on cancer-specific survival (CSS) in patients. Kaplan-Meier survival curves were constructed to assess cancer-specific mortality and were compared using the log-rank test.
resultsFrom 2004 to 2016, 10,593 people were diagnosed with MBC, and 402,797 were diagnosed with IDC. Patients with MBC had significantly higher 5-/10-year CSS rates (96.4%/93.4%) than those with IDC (89%/83.8%). Compared with IDC patients, MBC patients had less lymph node metastasis, an earlier stage, a higher rate of hormone receptor positivity and a lower expression rate of HER2. Univariate and multivariate analyses showed that age ≥ 60 years old (HR = 1.574, 95%CI: 1.238-2.001, P < 0.001), singled status (HR = 1.676, 95%CI: 1.330-2.112, P < 0.001) and advanced TNM/SEER stage were independent prognostic risk factors for MBC. In addition, positive estrogen receptor (HR = 0.577, 95%CI: 0.334-0.997, P = 0.049), positive progesterone receptor (HR = 0.740, 95%CI: 0.552-0.992, P = 0.044), surgical treatment (HR = 0.395, 95%CI: 0.288-0.542, P < 0.001) and radiotherapy (HR = 0.589, 95%CI: 0.459-0.756, P < 0.001) were identified as protective factors.
conclusionCompared with IDC, MBC has a better prognosis. For patients with MBC, we identified prognostic factors that can help clinicians better assess patient outcomes and guide individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.